Patents Assigned to BIOVAIL LABORATORIES
-
Patent number: 7645802Abstract: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.Type: GrantFiled: October 31, 2007Date of Patent: January 12, 2010Assignee: Biovail Laboratories International SRL.Inventors: Werner Oberegger, Paul Maes, Mohammad Ashty Saleh, Graham Jackson
-
Patent number: 7645901Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 21, 2007Date of Patent: January 12, 2010Assignee: Biovail Laboratories International S.R.L.Inventors: Werner Oberegger, Paul Maes, Stefano Turchetta, Pietro Massardo, Mohammad Ashty Saleh
-
Publication number: 20090269402Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially, surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.Type: ApplicationFiled: April 17, 2009Publication date: October 29, 2009Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Fang ZHOU, Werner Oberegger, Paul Maes
-
Publication number: 20090258067Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.Type: ApplicationFiled: April 17, 2009Publication date: October 15, 2009Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.LInventors: Fang ZHOU, Paul Maes, Steven Frisbee
-
Patent number: 7585897Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 21, 2007Date of Patent: September 8, 2009Assignee: Biovail Laboratories International S.r.l.Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
-
Patent number: 7579380Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: July 6, 2007Date of Patent: August 25, 2009Assignee: Biovail Laboratories International S.R.L.Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Stefano Turchetta, Graham Jackson, Pietro Massardo, Mohammad Ashty Saleh
-
Patent number: 7572935Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 14, 2007Date of Patent: August 11, 2009Assignee: Biovail Laboratories International S.R.L.Inventors: Werner Oberegger, Paul Maes, Stefano Turchetta, Pietro Massardo, Mohammad Ashty Saleh
-
Patent number: 7569611Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: June 14, 2007Date of Patent: August 4, 2009Assignee: Biovail Laboratories International SRL.Inventors: Werner Oberegger, Paul Maes, Mohammad Ashty Saleh
-
Patent number: 7569610Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: May 22, 2007Date of Patent: August 4, 2009Assignee: Biovail Laboratories International SRLInventors: Werner Oberegger, Paul Maes, Mohammad Ashty Saleh
-
Patent number: 7563823Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: May 22, 2007Date of Patent: July 21, 2009Assignee: Biovail Laboratories International SRL.Inventors: Werner Oberegger, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
-
Patent number: 7553992Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.Type: GrantFiled: May 31, 2007Date of Patent: June 30, 2009Assignee: Biovail Laboratories International S.R.L.Inventors: Werner Oberegger, Paul Maes, Stefano Turchetta, Pietro Massardo, Mohammad Ashty Saleh
-
Publication number: 20090142378Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: December 5, 2008Publication date: June 4, 2009Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventor: Steven FRISBEE
-
Patent number: 7537784Abstract: A modified-release tablet of bupropion hydrochloride comprising (i) a core comprising an effective amount of bupropion hydrochloride, a binder, a lubricant; and (ii) a control releasing coat surrounding said core; and (iii) a moisture barrier surrounding said control releasing coat, wherein the modified-release tablet is bioequivalent to Wellbutrin® or Zyban®/Wellbutrin®SR tablets.Type: GrantFiled: June 13, 2006Date of Patent: May 26, 2009Assignee: Biovail Laboratories International SRLInventors: Werner Oberegger, Okponanabofa Eradiri, Fang Zhou, Paul Maes
-
Publication number: 20090118256Abstract: A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to tType: ApplicationFiled: December 7, 2007Publication date: May 7, 2009Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Kenneth Stephen ALBERT, Theophilus Jones Gana, Paul Maes
-
Publication number: 20090004281Abstract: The present invention relates to a multiparticulate osmotic delivery system. The system is a modified release composition suitable for oral administration. The composition includes a core that includes at least one drug in combination with at least one pharmaceutically acceptable excipient. The composition further includes an osmotic subcoat surrounding the core, and a modified release overcoat surrounding the osmotic subcoated core.Type: ApplicationFiled: June 26, 2007Publication date: January 1, 2009Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Tien Nghiem, Graham JACKSON
-
Publication number: 20080292700Abstract: A controlled release pharmaceutical composition comprises (a) topiramate or a pharmaceutically acceptable salt thereof, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component. The polymer components are effective for controlled release of the pharmaceutically active substance from the composition.Type: ApplicationFiled: August 6, 2008Publication date: November 27, 2008Applicant: BIOVAIL LABORATORIESInventors: Tien NGHIEM, Graham Jackson
-
Publication number: 20080274177Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: July 9, 2008Publication date: November 6, 2008Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Fang Zhou, Paul Maes
-
Publication number: 20080175873Abstract: The present invention relates to a modified release composition of at least one form of venlafaxine, which is an enhanced absorption delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.Type: ApplicationFiled: November 30, 2007Publication date: July 24, 2008Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Fang Zhou, Paul Maes, Steven Frisbee
-
Publication number: 20080138411Abstract: The present invention relates to modified release pharmaceutical compositions for oral administration and more particularly to modified release pharmaceutical compositions of a form of at least one selective serotonin re-uptake inhibitor selected from the group consisting of a selective serotonin reuptake inhibitor, racemic mixtures thereof, enantiomers thereof, pharmaceutically-acceptable salts thereof and combinations thereof.Type: ApplicationFiled: December 19, 2003Publication date: June 12, 2008Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.LInventors: Paul Jose Maes, Goutam Muhuri
-
Publication number: 20080138404Abstract: An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof; one or more hydrophilic polymers; one or more pharmaceutically acceptable excipients; and a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material or a combination of a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material.Type: ApplicationFiled: November 27, 2007Publication date: June 12, 2008Applicant: BIOVAIL LABORATORIES INTERNATIONAL S.R.L.Inventors: Edwin WALSH, Ann Marie YOUNG, Graham JACKSON